Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals

Therapeutic Drug Monitoring

Volumn 29, Issue 3, 2007, Pages 361-367

  Dickinson, Laura ^a   Back, David ^a   Pozniak, Anton ^b,c   Khoo, Saye ^a   Boffito, Marta ^b,c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b PK Research Ltd ^*  (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Limited sampling strategy; Pharmacokinetics; Ritonavir; Saquinavir; Therapeutic drug monitoring

Indexed keywords

RITONAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; UNCLASSIFIED DRUG; PROTEINASE INHIBITOR;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SAMPLING; VALIDATION PROCESS; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; METHODOLOGY;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; GELS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MODELS, BIOLOGICAL; SAQUINAVIR;

EID: 34447530216     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3180683b25     Document Type: Article

References (23)

1. Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitors saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos. 1997;25:256-266.
2. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral adsorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
3. Williams GC, Liu A, Knipp G, et al. Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother. 2002;46:3456-3462.
4. Roche Pharmaceuticals. Invirase® summary of product characteristics. December 27, 2005. Available at: http://www.rocheuk.com/ProductDB/Documents/rx/ spc/Invirase_SPC.pdf. Accessed October 9, 2006.
5. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16:S5-37.
6. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006;28:468-473.
7. Lopez RM, Pou L, Azuaje C, et al. Limited sampling strategy to estimate the systemic exposure of atazanavir in HIV-infected patients. Abstract 84.7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, April 20-22, 2006.
8. Alexander CS, Montaner JS, Asselin JJ, et al. Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection. Ther Drug Monit. 2004;26:516-523.
9. Lopez RM, Pou L, Azuaje C, et al. Limited sampling strategy to estimate the systemic exposure of lopinavir in HIV infected patients. Abstract PE4.1/3. 10th European AIDS Conference (EACS), Dublin, Ireland, November 17-20, 2005.
10. Regazzi MB, Tinelli C, Villani P, et al. Limited sampling strategy for the estimation of systemic exposure to the protease inhibitor nelfinavir. Ther Drug Monit. 2005;27:571-575.
11. Lopez-Cortes LF, Ruiz-Valderas R, Marin-Niebla A, et al. Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. J AIDS. 2005;39:551-556.
12. Veldkamp AI, van Heeswijk RP, Mulder JW, et al. Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit. 2001;23:606-611.
13. Lee LS, Bertino JS Jr, Nafziger AN. Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol. 2006;46:229-234.
14. van Warmerdam LJ, ten Bokkel Huinink WW, Maes RA, et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol. 1994;120:427-433.
15. Regazzi MB, Villani P, Maserati R, et al. Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. Br J Clin Pharmacol. 1999;47:379-382.
16. Boffito M, Back D, Stainsby-Tron M, et al. Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects. Br J Clin Pharmacol. 2005;59:38-42.
17. Boffito M, Dickinson L, Hill A, et al. Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;37:1376-1384.
18. Boffito M, Dickinson L, Hill A, et al. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antivir Ther. 2004;9:423-429.
19. Boffito M, Maitland D, Dickinson L, et al. Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily. J Antimicrob Chemother. 2005;55:542-545.
20. Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;829:82-90.
21. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
22. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43:845-853.
23. Bittner B, Riek M, Holmes B, et al. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther. 2005;10:803-810.